NASDAQ · Financial Statements

GeneDx Holdings Corp. (WGS) Revenue, Earnings & Financial Statements

$47.29 NASDAQ: WGS Market Cap $1.42B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

GeneDx Holdings Corp. most recently reported annual revenue of $428.0M, a net loss of $21.0M. Revenue grew at an average annual rate of 19.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

GeneDx Holdings Corp.: Revenue rose from $196.0M in 2019 to $428.0M in 2025, a change of +118.4% over 6 years; net profit was positive in 0 of 7 reported years; operating margin moved from -15.5% to -2.8%, a shift of +12.7 percentage points; the most recent year shows a net loss of $21.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$196.0M$179.0M$212.0M$235.0M$203.0M$305.0M$428.0M
Operating Expenses$227.0M$421.0M$658.0M$902.0M$383.0M$329.0M$439.0M
Operating Profit−$30.0M−$242.0M−$446.0M−$668.0M−$181.0M−$23.0M−$12.0M
Operating Margin-15.5%-134.9%-210.3%-284.5%-89.2%-7.6%-2.8%
Other Income$1.0M$1.0M$201.0M$70.0M$4.0M−$29.0M−$9.0M
Interest$1.0M$2.0M$3.0M$3.0M$0$3.0M$3.0M
Depreciation$6.0M$12.0M$22.0M$59.0M$34.0M$22.0M$25.0M
Profit Before Tax−$30.0M−$241.0M−$245.0M−$598.0M−$177.0M−$53.0M−$21.0M
Tax rate (%)0.0%0.0%0.0%8.2%0.5%0.7%0.6%
Net Profit−$30.0M−$241.0M−$245.0M−$549.0M−$176.0M−$52.0M−$21.0M
EPS−$18.48−$146.94−$74.93−$53.63−$7.23−$1.94−$0.73

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$57.0M$62.0M$71.0M$77.0M$96.0M$87.0M$103.0M$117.0M$121.0M$102.0M$114.0M$123.0M
Operating Expenses$83.0M$76.0M$81.0M$85.0M$87.0M$92.0M$94.0M$120.0M$135.0M$128.0M$132.0M$134.0M
Operating Profit−$26.0M−$14.0M−$11.0M−$8.0M$9.0M−$5.0M$9.0M−$3.0M−$14.0M−$26.0M−$17.0M−$10.0M
Operating Margin-44.7%-21.9%-15.0%-10.1%9.2%-5.2%8.7%-2.8%-11.3%-25.6%-15.3%-8.5%
Interest$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M
Profit Before Tax−$26.0M−$20.0M−$29.0M−$8.0M$5.0M−$6.0M$11.0M−$7.0M−$18.0M−$62.0M−$18.0M−$12.0M
Tax rate (%)1.6%0.4%0.7%0.6%-0.4%-7.3%-2.3%-3.3%3.1%-1.4%-2.8%-0.2%
Net Profit−$26.0M−$20.0M−$29.0M−$8.0M$5.0M−$7.0M$11.0M−$8.0M−$18.0M−$63.0M−$18.0M−$12.0M
EPS−$0.99−$0.78−$1.10−$0.31$0.20−$0.23$0.36−$0.27−$0.59−$2.16−$0.60−$0.41

Over the 7 years reported for GeneDx Holdings Corp., cash stood at $105.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.46 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets—$252.0M$554.0M$545.0M$419.0M$419.0M$524.0M
Current Assets—$174.0M$484.0M$213.0M$182.0M$198.0M$268.0M
Cash—$108.0M$401.0M$137.0M$100.0M$85.0M$105.0M
Inventory—$25.0M$33.0M$14.0M$9.0M$11.0M$14.0M
Receivables—$32.0M$27.0M$43.0M$33.0M$38.0M$74.0M
Fixed Assets—$63.0M$63.0M$84.0M$59.0M$59.0M$69.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$11.0M$1.0M$1.0M$30.0M$56.0M$66.0M
Other Assets—$0$0$0$0$0$14.0M
Total Liabilities—$247.0M$166.0M$292.0M$191.0M$174.0M$216.0M
Current Liabilities—$73.0M$101.0M$144.0M$59.0M$55.0M$109.0M
Borrowings$0$43.0M$33.0M$77.0M$120.0M$116.0M$113.0M
Other Liabilities—$204.0M$133.0M$214.0M$71.0M$58.0M$102.0M
Equity—$0$0$0$0$0$0
Reserves—$4.0M$388.0M$254.0M$228.0M$245.0M$308.0M

For GeneDx Holdings Corp., operating cash flow was positive in 1 of 7 reported years; free cash flow in the latest year was $14.0M; free cash flow was positive in 1 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow−$19.0M−$93.0M−$190.0M−$319.0M−$180.0M−$28.0M$33.0M
Investing Cash Flow−$31.0M−$64.0M−$42.0M−$156.0M−$49.0M−$36.0M−$81.0M
Financing Cash Flow$31.0M$0$65.0M$3.0M$0$1.0M$0
Net Cash Flow$114.0M$4.0M$283.0M−$263.0M−$38.0M−$14.0M$20.0M
Free Cash Flow−$34.0M−$125.0M−$211.0M−$333.0M−$186.0M−$34.0M$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-21.00
FCF Yield-6.51%
Quick Ratio3.85
Interest Coverage-16.14
Return 1Y-59.82%
Return 3Y4023.62%
Return 5Y-79.17%

GeneDx Holdings Corp. (WGS) financials — frequently asked questions

What is GeneDx Holdings Corp.'s annual revenue?

GeneDx Holdings Corp. (WGS) reported annual revenue of $428.0M in its most recent fiscal year.

What is GeneDx Holdings Corp.'s net profit?

GeneDx Holdings Corp. (WGS) reported a net loss of $21.0M in its most recent fiscal year.

What is WGS EV/EBITDA?

GeneDx Holdings Corp.'s enterprise value to EBITDA (EV/EBITDA) ratio is -21.00. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Diagnostics & Research stocks

TMO revenue $44.6BDHR revenue $24.6BIDXX revenue $4.3BA revenue $6.9BWAT revenue $3.2BIQV revenue $16.3BNTRA revenue $2.3BMTD revenue $4.0BILMN revenue $4.3BLH revenue $14.0BAll Medical - Diagnostics & Research stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
WGS Overview WGS Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.